Verve Therapeutics (VERV) News Today $5.60 +0.06 (+1.08%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 8 at 5:24 PM | insidermonkey.comVerve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short SellersSeptember 8 at 4:00 PM | prnewswire.comVERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 8 at 12:22 PM | stockhouse.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsSeptember 6 at 8:54 PM | prnewswire.comVERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud LawsuitSeptember 6 at 11:33 AM | stockhouse.comVerve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERVSeptember 6 at 11:33 AM | msn.comVerve Therapeutics’ (VERV) Gene-Editing Therapies Could Be a Game ChangerSeptember 6 at 5:45 AM | prnewswire.comInvestors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERVSeptember 5 at 4:48 PM | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERVSeptember 5 at 1:32 PM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit – VERVSeptember 5 at 8:30 AM | prnewswire.comVerve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERVSeptember 5 at 5:45 AM | prnewswire.comClass Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for Investors - Contact The Gross Law FirmSeptember 4, 2024 | globenewswire.comVERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class ActionSeptember 4, 2024 | prnewswire.comVERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law FirmSeptember 3, 2024 | tmcnet.comREMINDER - Verve Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the VERV Class Action LawsuitSeptember 3, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | globenewswire.comVERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERVSeptember 3, 2024 | globenewswire.comVERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 3, 2024 | globenewswire.comVERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their RightsSeptember 1, 2024 | globenewswire.comROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERVSeptember 1, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsAugust 31, 2024 | prnewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsAugust 30, 2024 | stockhouse.comA Case For Fraud Has Been Filed Against Verve Therapeutics Inc And Impacted Shareholders Are Invited To Help The Schall Law FirmAugust 30, 2024 | prnewswire.comVERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 30, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Shares Up 6.9%Verve Therapeutics (NASDAQ:VERV) Shares Up 6.9%August 30, 2024 | tmcnet.comVERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 29, 2024 | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsAugust 28, 2024 | globenewswire.comVERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the FirmAugust 28, 2024 | msn.comLevi & Korsinsky LLP Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming DeadlineAugust 28, 2024 | prnewswire.comVERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. in Securities Fraud LawsuitAugust 28, 2024 | globenewswire.comStockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.August 28, 2024 | globenewswire.comVERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 28, 2024 | globenewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. (VERV)August 28, 2024 | tmcnet.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsAugust 28, 2024 | globenewswire.comSHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Verve Therapeutics, Inc. (VERV) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmAugust 27, 2024 | globenewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERVAugust 25, 2024 | stockhouse.comVerve Therapeutics Inc Is Being Inquired Into For Potential Securities Law Violations And The Schall Law Firm Is Seeking Shareholders To ParticipateAugust 25, 2024 | stockhouse.comThe Schall Law Firm Invites Investors In Verve Therapeutics Inc To Join The Securities Fraud InvestigationAugust 22, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Trims Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)Sumitomo Mitsui Trust Holdings Inc. lowered its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,115,466 shares of the comAugust 21, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Moderate Buy" by AnalystsVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the coAugust 12, 2024 | marketwatch.comEsperion Therapeutics Shares Fall on Wider-Than-Expected 2Q LossAugust 12, 2024 | marketbeat.comCanaccord Genuity Group Lowers Verve Therapeutics (NASDAQ:VERV) Price Target to $29.00Canaccord Genuity Group lowered their target price on shares of Verve Therapeutics from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Monday.August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong FinancialsAugust 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPSVerve Therapeutics (NASDAQ:VERV - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.09. The company had revenue of $6.70 million during the quarter, compared to analyst estimates of $2.40 million. Verve Therapeutics had a negative net margin of 1,226.51% and a negative return on equity of 37.35%. Verve Therapeutics's quarterly revenue was up 219.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.87) earnings per share.August 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) PT Lowered to $20.00Royal Bank of Canada dropped their price target on Verve Therapeutics from $25.00 to $20.00 and set an "outperform" rating on the stock in a research report on Friday.August 8, 2024 | investorplace.comVERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Verve Therapeutics, Inc. (NASDAQ: VERV)August 8, 2024 | markets.businessinsider.comVerve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | prnewswire.comVerve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERVAugust 5, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Vanguard Group Inc. lifted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 15.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,331,312 shares of the company's stock after buying an additi Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s weapon lurks in abandoned America (Ad)Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place… Go here now to watch my new documentary VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼-0.010.54▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼194▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Recursion Pharmaceuticals News Today Mirum Pharmaceuticals News Today Zai Lab News Today Galapagos News Today Kiniksa Pharmaceuticals News Today Akero Therapeutics News Today Immunocore News Today Keros Therapeutics News Today Arvinas News Today Syndax Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
